Related Experiment Videos
[The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)]
Abstract:
We report about the in-vitro-sensitivity tests of 1756 Enterobacteriaceae and Pseudomonas strains to amikacin, gentamicin, tobramycin and sisomicin. It was established, that amikacin is more effective than gentamicin, tobramycin and sisomicin in case of infections with Klebsiella, Proteus species, Psuedomonas strains and Enterobacter. The four aminoglycosides are well active against E. coli. Hospital acquired infections with Serratia are a domain of amikacin. Tobramycin is more effective than gentamicin and sisomicin against Pseudomonas infections. Amikacin is the drug of choice against gentamicin-resistent strains, which are also not infrequently resistant to other aminoglycosides. Resistance to gentamicin-tobramycin and gentamicin-tobramycin-sisomicin, is most frequent among Klebsiella strains. The cross-resistance rate is considerably higher among Enterobacteriaceae strains than among Pseudomonas species. The lowest rate of resistance (2.1%) and the high antimicrobial activity are the considerable advantages of amikacin.
Insights
Amikacin demonstrates superior in-vitro efficacy against various bacterial strains, including Klebsiella and Pseudomonas. It is the preferred choice for treating infections caused by gentamicin-resistant bacteria.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Antibiotic resistance is a growing global health concern.
- Aminoglycosides are crucial in treating serious bacterial infections.
- Enterobacteriaceae and Pseudomonas are common causes of hospital-acquired infections.
Purpose:
- To evaluate the in-vitro activity of amikacin, gentamicin, tobramycin, and sisomicin against 1756 bacterial isolates.
- To compare the effectiveness of these four aminoglycosides against specific bacterial species.
- To identify optimal antibiotic choices for infections caused by resistant strains.
Summary:
- Amikacin showed greater efficacy than gentamicin, tobramycin, and sisomicin against Klebsiella, Proteus, Pseudomonas, and Enterobacter species.
- All four aminoglycosides were active against E. coli.
- Amikacin is highly effective against Serratia and gentamicin-resistant strains, with a low resistance rate (2.1%).
- Cross-resistance was more prevalent in Enterobacteriaceae than in Pseudomonas species.
Impact:
- Provides evidence for amikacin as a preferred agent against specific Gram-negative pathogens.
- Informs clinical decisions for treating infections caused by aminoglycoside-resistant bacteria.
- Highlights the importance of susceptibility testing in guiding antibiotic therapy.